Cervical Cancer Screening Test Receives Approval for the European Sector
|
By LabMedica International staff writers Posted on 09 Sep 2014 |
|
Image: Example of chromosomes stained with the FHACT combination probe: 3q26 (TERC) (red), 5p15 (D5S2095) (green), 20q13 (D20S911) (gold), and CEP7 (aqua) (Photo courtesy of Cancer Genetics Inc.).
A screening test that detects the clonal chromosomal aberrations (gains or amplifications) commonly found in cervical cancer specimens has received CE-marking that allows it to be distributed as a diagnostic test in the 28 countries making up the European Economic Area.
The Cancer Genetics Inc. (Rutherford, NJ, USA) FISH (fluorescence in situ hybridization)-based HPV-Associated Cancer Test (FHACT) utilizes the only four color FISH probe that can be used for cervical cancer screening as additional triage before referral for colposcopy.
The FISH analysis is performed on nuclei of cells derived from a liquid pap specimen using the FHACT combination probe manufactured by CGI Italia (Milan, Italy), a wholly owned subsidiary of Cancer Genetics Inc. The probe comprises 3q26 (TERC) (red), 5p15 (D5S2095) (green), 20q13 (D20S911) (gold), and CEP7 (aqua).
The FISH probe has been optimized to identify copy number gains of 3q26, 5p15, chromosome 7, and 20q13. In normal diploid interphase and metaphase cells, FHACT generates two red, two green, two blue, and two gold signals corresponding to the normal chromosomes 3, 5, 7 and 20 respectively. In cells with gain or amplification of 3q26, 5p15, 20q13 and/or chromosome 7, the number of red, green, gold, and/or blue signals will be greater than two each.
The FHACT test identifies irreversible genomic changes associated with progression to cancer. In addition to identifying those women most at risk for cervical disease, it can help reduce unnecessary, invasive testing and over-treatment in women who do not show the genomic abnormalities associated with disease progression.
"We are committed to the highest level of quality in the development and manufacture of our DNA-FISH probes and tests. Our probes are manufactured to meet or exceed all established quality and performance specifications, and comply with relevant safety and regulatory requirements in order to qualify them for CE marking," said Panna Sharma, CEO of Cancer Genetics, Inc. "Cervical cancer screening is evolving, but there remains a need for more definitive and genomically informed diagnosis. Our proprietary cervical cancer test, FHACT, was designed in response to this need. Having it affixed with the CE-mark will allow us to expand our marketing and sales in Europe, and allow for greater adoption of the test globally."
The FHACT method is protected by several US and international patents.
Related Links:
Cancer Genetics Inc.
CGI Italia
The Cancer Genetics Inc. (Rutherford, NJ, USA) FISH (fluorescence in situ hybridization)-based HPV-Associated Cancer Test (FHACT) utilizes the only four color FISH probe that can be used for cervical cancer screening as additional triage before referral for colposcopy.
The FISH analysis is performed on nuclei of cells derived from a liquid pap specimen using the FHACT combination probe manufactured by CGI Italia (Milan, Italy), a wholly owned subsidiary of Cancer Genetics Inc. The probe comprises 3q26 (TERC) (red), 5p15 (D5S2095) (green), 20q13 (D20S911) (gold), and CEP7 (aqua).
The FISH probe has been optimized to identify copy number gains of 3q26, 5p15, chromosome 7, and 20q13. In normal diploid interphase and metaphase cells, FHACT generates two red, two green, two blue, and two gold signals corresponding to the normal chromosomes 3, 5, 7 and 20 respectively. In cells with gain or amplification of 3q26, 5p15, 20q13 and/or chromosome 7, the number of red, green, gold, and/or blue signals will be greater than two each.
The FHACT test identifies irreversible genomic changes associated with progression to cancer. In addition to identifying those women most at risk for cervical disease, it can help reduce unnecessary, invasive testing and over-treatment in women who do not show the genomic abnormalities associated with disease progression.
"We are committed to the highest level of quality in the development and manufacture of our DNA-FISH probes and tests. Our probes are manufactured to meet or exceed all established quality and performance specifications, and comply with relevant safety and regulatory requirements in order to qualify them for CE marking," said Panna Sharma, CEO of Cancer Genetics, Inc. "Cervical cancer screening is evolving, but there remains a need for more definitive and genomically informed diagnosis. Our proprietary cervical cancer test, FHACT, was designed in response to this need. Having it affixed with the CE-mark will allow us to expand our marketing and sales in Europe, and allow for greater adoption of the test globally."
The FHACT method is protected by several US and international patents.
Related Links:
Cancer Genetics Inc.
CGI Italia
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Latest Pathology News
- Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
- AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer
- New Journal Addresses Evolving Needs in Clinical and Translational Pathology
- AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells
- AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
- New Review Highlights Intelligent Agents as Next Step for Digital Pathology
- Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
- AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals
- 30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
- AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
- AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
- FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
- AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
- AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
- PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
- AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Channels
Clinical Chemistry
view channel
New Blood Biomarker Predicts May Predict Preeclampsia and Fetal Growth Restriction
Preeclampsia and fetal growth restriction are major drivers of stillbirth and serious maternal morbidity, yet clinicians still lack reliable early predictors to guide targeted surveillance.... Read more
Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction
Takotsubo syndrome, often called broken-heart syndrome, mimics myocardial infarction and can be difficult to triage in emergency settings. It accounts for about 2% of suspected heart attacks and up to... Read more
Molecular Diagnostics
view channel
Automated System Streamlines DNA Recovery for MRD-Sensitive Testing
Molecular laboratories are under pressure to detect extremely low levels of residual disease, yet pre-analytical recovery of cell-free and genomic DNA from large-volume blood and plasma remains a persistent... Read more
New Liquid Biopsy Platform Uses Red Blood Cells to Detect Hidden Cancer Signals
Plasma-based liquid biopsy can miss clinically actionable tumor signals, particularly in early-stage disease and low-shedding tumors, limiting its utility for routine monitoring. Clinical laboratories... Read more
Hematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Immunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read more
Microbiology
view channel
Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more
Technology
view channel
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read more
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Industry
view channel
New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
Rapid and accurate classification of central nervous system tumors remains a challenge, particularly in children where histology alone can misclassify aggressiveness and drive overtreatment.... Read more
